JP2018524390A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524390A5
JP2018524390A5 JP2018503191A JP2018503191A JP2018524390A5 JP 2018524390 A5 JP2018524390 A5 JP 2018524390A5 JP 2018503191 A JP2018503191 A JP 2018503191A JP 2018503191 A JP2018503191 A JP 2018503191A JP 2018524390 A5 JP2018524390 A5 JP 2018524390A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
group
acceptable salt
hydroxyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018503191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524390A (ja
JP6746679B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/090962 external-priority patent/WO2017012576A1/en
Publication of JP2018524390A publication Critical patent/JP2018524390A/ja
Publication of JP2018524390A5 publication Critical patent/JP2018524390A5/ja
Application granted granted Critical
Publication of JP6746679B2 publication Critical patent/JP6746679B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018503191A 2015-07-23 2016-07-22 化合物 Expired - Fee Related JP6746679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015084893 2015-07-23
CNPCT/CN2015/084893 2015-07-23
PCT/CN2016/090962 WO2017012576A1 (en) 2015-07-23 2016-07-22 Compounds

Publications (3)

Publication Number Publication Date
JP2018524390A JP2018524390A (ja) 2018-08-30
JP2018524390A5 true JP2018524390A5 (enExample) 2019-08-29
JP6746679B2 JP6746679B2 (ja) 2020-08-26

Family

ID=57833742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503191A Expired - Fee Related JP6746679B2 (ja) 2015-07-23 2016-07-22 化合物

Country Status (11)

Country Link
US (1) US10975081B2 (enExample)
EP (1) EP3325449B1 (enExample)
JP (1) JP6746679B2 (enExample)
KR (1) KR20180030201A (enExample)
CN (1) CN108137510B (enExample)
AU (1) AU2016295604B2 (enExample)
BR (1) BR112018001303A2 (enExample)
CA (1) CA2993269A1 (enExample)
ES (1) ES2862188T3 (enExample)
RU (1) RU2725616C2 (enExample)
WO (1) WO2017012576A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248936A (zh) * 2017-01-25 2019-09-17 葛兰素史密斯克莱知识产权发展有限公司 化合物
CN110402247A (zh) * 2017-01-25 2019-11-01 葛兰素史密斯克莱知识产权发展有限公司 化合物
JP2020506966A (ja) * 2017-01-25 2020-03-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化合物
CN110446700A (zh) 2017-01-25 2019-11-12 葛兰素史密斯克莱知识产权发展有限公司 化合物
BR112019015314A2 (pt) * 2017-01-25 2020-05-19 Glaxosmithkline Ip Dev Ltd compostos para inibir a atividade da quinase lrrk2
CN106866547B (zh) * 2017-03-15 2020-11-10 江苏省农用激素工程技术研究中心有限公司 2-乙氧基-4,6-二氯嘧啶的合成方法
US20200199136A1 (en) * 2017-08-28 2020-06-25 Acurastem Inc. Pikfyve kinase inhibitors
US20210261553A1 (en) * 2018-05-15 2021-08-26 E-Scape Bio, Inc. Fused tetrazoles as lrrk2 inhibitors
KR20190131981A (ko) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
WO2020092136A1 (en) * 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP7682097B2 (ja) 2019-03-27 2025-05-23 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
WO2020247298A2 (en) 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CA3144093A1 (en) * 2019-07-01 2021-01-07 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
AU2020311940A1 (en) * 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
EP4103281A1 (en) * 2020-02-11 2022-12-21 Acurastem Inc. Pikfyve kinase inhibitors
WO2021178780A1 (en) * 2020-03-06 2021-09-10 ESCAPE Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
CA3181165A1 (en) * 2020-04-24 2021-10-28 The Regents Of The University Of California Nurr1 receptor modulators and uses thereof
WO2022155419A1 (en) * 2021-01-15 2022-07-21 ESCAPE Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors
WO2025201511A1 (zh) * 2024-03-29 2025-10-02 上海京新生物医药有限公司 吲唑衍生物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
US20110130384A1 (en) * 2008-06-25 2011-06-02 Takeda Pharmaceutical Company Limited Amide compound
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
EP2489663A1 (en) * 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2867232B1 (en) 2012-06-27 2018-08-08 F.Hoffmann-La Roche Ag 5-azaindazole compounds and methods of use
WO2014134774A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
WO2016036586A1 (en) 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity

Similar Documents

Publication Publication Date Title
JP2018524390A5 (enExample)
RU2018106453A (ru) Соединения
JP2016506960A5 (enExample)
JP2016530259A5 (enExample)
JP2016515561A5 (enExample)
JP2019509276A5 (enExample)
JP2014511892A5 (enExample)
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
JP2019524883A5 (enExample)
JP2016540742A5 (enExample)
JP2016530283A5 (enExample)
JP2016506962A5 (enExample)
JP2018502877A5 (enExample)
JP2020502092A5 (enExample)
JP2015500843A5 (enExample)
JP2016506961A5 (enExample)
JP2016040288A5 (enExample)
JP2015537020A5 (enExample)
JP2016506935A5 (enExample)
JP2013509392A5 (enExample)
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
JP2015504091A5 (enExample)
JP2012513416A5 (enExample)
JP2015501833A5 (enExample)
RU2016134751A (ru) Соединения